Literature DB >> 27683054

High mucin-7 expression is an independent predictor of adverse clinical outcomes in patients with clear-cell renal cell carcinoma.

SonTung NguyenHoang1, Yidong Liu2, Le Xu3, Yuan Chang1, Lin Zhou1, Zheng Liu2, Zongming Lin4, Jiejie Xu5.   

Abstract

Mucin-7 is a member of the secreted mucins family. Mucins might play a crucial role during tumor development and its aberrant expression was observed in several types of tumor. Our study aims to evaluate the prognostic significance of Mucin-7 expression in postoperative clear-cell renal cell carcinoma (ccRCC) patients. In this retrospective study, we enrolled 392 patients with ccRCC undergoing nephrectomy between 2008 and 2009 in a single center. The median follow-up was 73 months (range 39-74 months). Mucin-7 expression was evaluated by immunohistochemistry protocol on ccRCC specimens. Kaplan-Meier survival analysis was conducted to compare survival curves. Univariate and multivariate Cox regression models were applied to assess the impact of prognostic factors in overall survival (OS) and recurrence-free survival (RFS). A nomogram was then constructed based on the independent prognosticators identified on multivariate analysis. The results displayed that Mucin-7 expression was significantly associated with tumor size (p = 0.034), pT stage (p = 0.004), TNM stage (p = 0.008), and necrosis (p = 0.043). Patients with high Mucin-7 expression had significant worse outcomes in both OS (p < 0.001) and RFS (p < 0.001) compared to those with low Mucin-7 expression. MUC7 expression was considered as an independent predictive factor for OS (HR 2.286; 95 %CI 1.167-4.475; p = 0.016) and RFS (HR 2.055; 95 %CI 1.086-3.887; p = 0.027). A nomogram integrating Mucin-7 expression and other independent prognosticators was constructed. In summary, the high Mucin-7 expression is a potential prognosticator of adverse clinical outcome in ccRCC patients after surgery.

Entities:  

Keywords:  Clear-cell renal cell carcinoma; Mucin-7; Overall survival; Prognostic biomarker; Recurrence-free survival

Mesh:

Substances:

Year:  2016        PMID: 27683054     DOI: 10.1007/s13277-016-5375-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

Review 1.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

2.  Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor.

Authors:  M Retz; J Lehmann; E Amann; B Wullich; C Röder; M Stöckle
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma.

Authors:  Le Xu; Yu Zhu; Lian Chen; Huimin An; Weijuan Zhang; Guomin Wang; Zongming Lin; Jiejie Xu
Journal:  Ann Surg Oncol       Date:  2014-03-11       Impact factor: 5.344

Review 4.  Renal cell carcinoma.

Authors:  Paul Cairns
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

5.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

6.  Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms.

Authors:  F Safi; W Schlosser; G Kolb; H G Beger
Journal:  J Gastrointest Surg       Date:  1997 Mar-Apr       Impact factor: 3.452

Review 7.  Renal cell carcinoma.

Authors:  Brian I Rini; Steven C Campbell; Bernard Escudier
Journal:  Lancet       Date:  2009-03-05       Impact factor: 79.321

8.  External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.

Authors:  Vincenzo Ficarra; Guido Martignoni; Christine Lohse; Giacomo Novara; Maurizio Pea; Stefano Cavalleri; Walter Artibani
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

Review 9.  Renal cell carcinoma: Review of etiology, pathophysiology and risk factors.

Authors:  Nadezda Petejova; Arnost Martinek
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2015-11-03       Impact factor: 1.245

Review 10.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Authors:  Mildred Felder; Arvinder Kapur; Jesus Gonzalez-Bosquet; Sachi Horibata; Joseph Heintz; Ralph Albrecht; Lucas Fass; Justanjyot Kaur; Kevin Hu; Hadi Shojaei; Rebecca J Whelan; Manish S Patankar
Journal:  Mol Cancer       Date:  2014-05-29       Impact factor: 27.401

View more
  6 in total

1.  Spatial Distribution of Private Gene Mutations in Clear Cell Renal Cell Carcinoma.

Authors:  Ariane L Moore; Aashil A Batavia; Jack Kuipers; Jochen Singer; Elodie Burcklen; Peter Schraml; Christian Beisel; Holger Moch; Niko Beerenwinkel
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.575

2.  High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.

Authors:  Zhiying Xu; Yidong Liu; Yuanfeng Yang; Jieti Wang; Guodong Zhang; Zheng Liu; Hangcheng Fu; Zewei Wang; Haiou Liu; Jiejie Xu
Journal:  Oncotarget       Date:  2017-01-31

3.  The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Zhenlei Zha; Hu Zhao; Yejun Feng; Lijin Zhang; Bin Wu
Journal:  Cancer Manag Res       Date:  2018-06-22       Impact factor: 3.989

Review 4.  Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Lijin Zhang; Zhenlei Zha; Wei Qu; Hu Zhao; Jun Yuan; Yejun Feng; Bin Wu
Journal:  BMC Cancer       Date:  2018-09-03       Impact factor: 4.430

5.  Screening and identification of biomarkers associated with clinicopathological parameters and prognosis in oral squamous cell carcinoma.

Authors:  Qiqi Wu; Ruoyan Cao; Juan Chen; Xiaoli Xie
Journal:  Exp Ther Med       Date:  2019-09-11       Impact factor: 2.447

6.  Screening the key genes of prognostic value in the microenvironment for head and neck squamous cell carcinoma.

Authors:  Di Meng; Tongjun Liu; Feng Ma; Mingguo Wang
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.